vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and Marygold Companies, Inc. (MGLD). Click either name above to swap in a different company.
Marygold Companies, Inc. is the larger business by last-quarter revenue ($7.6M vs $3.9M, roughly 2.0× Opus Genetics, Inc.). On growth, Marygold Companies, Inc. posted the faster year-over-year revenue change (-4.5% vs -10.2%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -1.5%).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
IRD vs MGLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $7.6M |
| Net Profit | — | $-576.0K |
| Gross Margin | — | 74.0% |
| Operating Margin | — | -8.3% |
| Net Margin | — | -7.5% |
| Revenue YoY | -10.2% | -4.5% |
| Net Profit YoY | 53.0% | 67.0% |
| EPS (diluted) | — | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $7.6M | ||
| Q3 25 | $3.1M | $7.0M | ||
| Q2 25 | $2.9M | $7.2M | ||
| Q1 25 | $4.4M | $7.0M | ||
| Q4 24 | $4.3M | $8.0M | ||
| Q3 24 | $3.9M | $7.9M | ||
| Q2 24 | $1.1M | $8.3M | ||
| Q1 24 | $1.7M | $7.9M |
| Q4 25 | — | $-576.0K | ||
| Q3 25 | $-17.5M | $-356.0K | ||
| Q2 25 | $-7.4M | $-1.5M | ||
| Q1 25 | $-8.2M | $-1.0M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $-7.5M | $-1.6M | ||
| Q2 24 | $-7.8M | $-1.9M | ||
| Q1 24 | $-7.1M | $-529.0K |
| Q4 25 | — | 74.0% | ||
| Q3 25 | — | 77.0% | ||
| Q2 25 | — | 67.8% | ||
| Q1 25 | — | 75.0% | ||
| Q4 24 | — | 74.1% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 72.5% | ||
| Q1 24 | — | 70.5% |
| Q4 25 | — | -8.3% | ||
| Q3 25 | -269.9% | -18.2% | ||
| Q2 25 | -309.0% | -16.5% | ||
| Q1 25 | -227.2% | -21.4% | ||
| Q4 24 | — | -22.8% | ||
| Q3 24 | -207.1% | -27.4% | ||
| Q2 24 | -748.9% | -33.3% | ||
| Q1 24 | -450.5% | -18.7% |
| Q4 25 | — | -7.5% | ||
| Q3 25 | -566.9% | -5.1% | ||
| Q2 25 | -257.5% | -20.4% | ||
| Q1 25 | -187.5% | -14.4% | ||
| Q4 24 | — | -21.8% | ||
| Q3 24 | -194.6% | -20.1% | ||
| Q2 24 | -698.3% | -22.5% | ||
| Q1 24 | -415.3% | -6.7% |
| Q4 25 | — | $-0.01 | ||
| Q3 25 | $-0.25 | $-0.01 | ||
| Q2 25 | $-0.12 | $-0.04 | ||
| Q1 25 | $-0.24 | $-0.02 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | $-0.29 | $-0.04 | ||
| Q2 24 | $-0.30 | $-0.05 | ||
| Q1 24 | $-0.29 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.3M | $22.7M |
| Total Assets | $50.2M | $27.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $11.6M | ||
| Q3 25 | $30.8M | $12.5M | ||
| Q2 25 | $32.4M | $12.8M | ||
| Q1 25 | $41.8M | $15.6M | ||
| Q4 24 | $30.3M | $14.9M | ||
| Q3 24 | $36.6M | $17.5M | ||
| Q2 24 | $41.4M | $15.0M | ||
| Q1 24 | $47.2M | $16.1M |
| Q4 25 | $15.3M | $22.7M | ||
| Q3 25 | $6.0M | $22.9M | ||
| Q2 25 | $17.5M | $23.0M | ||
| Q1 25 | $5.1M | $24.3M | ||
| Q4 24 | $6.7M | $23.4M | ||
| Q3 24 | $34.3M | $25.5M | ||
| Q2 24 | $40.6M | $26.6M | ||
| Q1 24 | $46.1M | $28.4M |
| Q4 25 | $50.2M | $27.8M | ||
| Q3 25 | $36.1M | $28.4M | ||
| Q2 25 | $38.7M | $30.4M | ||
| Q1 25 | $48.2M | $33.5M | ||
| Q4 24 | $36.9M | $33.0M | ||
| Q3 24 | $40.4M | $35.9M | ||
| Q2 24 | $44.8M | $32.9M | ||
| Q1 24 | $51.8M | $33.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-908.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-908.0K | ||
| Q3 25 | $-6.2M | $-533.0K | ||
| Q2 25 | $-10.3M | $-3.3M | ||
| Q1 25 | $-9.0M | $-1.2M | ||
| Q4 24 | $-25.6M | $-770.0K | ||
| Q3 24 | $-5.1M | $-893.0K | ||
| Q2 24 | $-7.3M | $-1.9M | ||
| Q1 24 | $-5.7M | $-658.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-562.0K | ||
| Q2 25 | — | $-3.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-776.0K | ||
| Q3 24 | — | $-940.0K | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -8.1% | ||
| Q2 25 | — | -46.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -9.7% | ||
| Q3 24 | — | -11.9% | ||
| Q2 24 | — | -23.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRD
Segment breakdown not available.
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
